ArticleHead & neck2025
The Role of Adjuvant Radiotherapy for Early-Stage Oral Cavity Cancer With Minor Adverse Features; A Single Institute Experience.
Article in Head & neck, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe role of post-operative radiotherapy (PORT) in early-stage (T1-T2N0M0) oral tongue squamous cell carcinoma (OTSCC) with minor adverse features (MAF) including perineural invasion (PNI) and poorly differentiated carcinoma (PDC) is not well described. We aimed to study the role of PORT among these patients.
methodsA retrospective review of patients treated for early-stage OTSCC between 2000 and 2022 in a tertiary-care referral center while comparing patients treated by surgery and PORT with patients treated by surgery alone.
resultsOne hundred fifty-four patients were included and 36 (23.4%) received PORT. The PORT subgroup had a significantly higher rate of MAF. Survival rates were similar between the two sub-groups. PORT demonstrated a trend toward improved overall survival (odds ratio = 0.406, p = 0.07). Patients with PNI or PDC treated with PORT experienced improved survival rates.
conclusionPORT has an important role when treating early-stage OTSCC with MAF. It should be considered especially among patients with PNI or PDC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.